TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7587232

Group type: EXPERIMENTAL
Intervention: Unfractionated porcine heparin (20 U/kg for ex vivo evaluation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Unfractionated porcine heparin (varying doses for in vitro evaluation)
Number of subjects: 35
Study: 2406328

Group type: EXPERIMENTAL
Intervention: Enprofylline 300 mg b.i.d.
Number of subjects: 242

Group type: COMPARATOR
Intervention: Theophylline 300 mg b.i.d.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Enprofylline 450 mg b.i.d.
Number of subjects: 242

Group type: COMPARATOR
Intervention: Theophylline 450 mg b.i.d.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 242
Study: 31621606

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) for ten weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 40
Study: 30024661

Group type: EXPERIMENTAL
Intervention: ELF‐EMF therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (kinesiotherapy only)
Number of subjects: 57
Study: 25669645

Group type: EXPERIMENTAL
Intervention: Radial artery (RA)
Number of subjects: 4006
Study: 23263227

Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy assistance
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional TKA without fluoroscopy
Number of subjects: 106
Study: 22920798

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) delivery of insulin lispro
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subcutaneous (SC) delivery of insulin lispro
Number of subjects: 22
Study: 20022994

Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 20
Study: 17592778

Group type: EXPERIMENTAL
Intervention: Housing First intervention (permanent, independent housing with support services)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 0
Study: 16311144

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potential (SSEP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Electromyography and nerve conduction studies (EMG-NCS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Agreement between SSEP and EMG-NCS
Number of subjects: 46
Study: 12463582

Group type: EXPERIMENTAL
Intervention: Autogenous hamstring graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patellar tendon graft
Number of subjects: 0
Study: 9854758

Group type: EXPERIMENTAL
Intervention: titrated-dose oxycodone and sustained-release morphine sulfate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: set-dose oxycodone
Number of subjects: 36

Group type: COMPARATOR
Intervention: naproxen only
Number of subjects: 36
Study: 7875765

Group type: EXPERIMENTAL
Intervention: Moderate-intensity training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sedentary period
Number of subjects: 0
Study: 2361891

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (dextrose, 5 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine plus cold exposure (5 degrees C for 2 h)
Number of subjects: 6
Study: 44580

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31056661

Group type: EXPERIMENTAL
Intervention: 1-year adjunction of AZA to glucocorticoids (GC)
Number of subjects: 50
Study: 28099276

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injected in both submandibular and parotid glands
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (parotid injections only)
Number of subjects: 40
Study: 26079801

Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet System (SSTS) 15 μg
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 23693018

Group type: EXPERIMENTAL
Intervention: neoadjuvant DE combined with rh-endostatin (7.5 mg/m2, d1-d14, every 3 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: neoadjuvant DE (docetaxel: 75 mg/m2, d1, epirubicin: 75 mg/m2, d1, every 3 weeks)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: neoadjuvant DE combined with rh-endostatin
Number of subjects: 68

Group type: COMPARATOR
Intervention: neoadjuvant DE
Number of subjects: 68
Study: 21569445

Group type: EXPERIMENTAL
Intervention: Depression Care Management (DCM) intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 320
Study: 18594954

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 1015
Study: 15904632

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg intravenous bolus)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Heparin (60 U/kg intravenous bolus)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 200
Study: 12610035

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (1.57 mg or 45 IU on each of the 2 dosing days in part 1; 4.7 mg or 135 IU in part 2)
Number of subjects: 45
Study: 10498559

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (n = 55)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline placebo (n = 47)
Number of subjects: 102
Study: 8607679

Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood for 18 hours
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood
Number of subjects: 120
Study: 2006659

Group type: EXPERIMENTAL
Intervention: Active treatment (triamterene and hydrochlorothiazide)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Diuretics plus methyldopa
Number of subjects: 840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study: 6161574

Group type: EXPERIMENTAL
Intervention: Experimental groups (3 of 4) involved in selecting topics and receiving feedback during the course
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Experimental groups (3 of 4)
Number of subjects: 44
Study: 29794296

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,300 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,300 mg/day and 900 mg/day)
Number of subjects: 0
Study: 28960739

Group type: EXPERIMENTAL
Intervention: Safewards intervention implemented in 13 wards for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison group of 31 wards with seclusion facilities
Number of subjects: 44
Study: 26561613

Group type: EXPERIMENTAL
Intervention: UNIMMAP (multiple micronutrient preparation)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study: 22769574

Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 20
Study: 20869928

Group type: EXPERIMENTAL
Intervention: 5% topical tocotrienol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 18230197

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 3
Study: 16740175

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 251

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 251
Study: 15231900

Group type: EXPERIMENTAL
Intervention: IL-8 group (antibiotic therapy when IL-8 >70 pg/mL and/or CRP >10 mg/L)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Standard group (antibiotic therapy according to the guidelines of each center)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: IL-8 group
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 1291
Study: 11702799

Group type: EXPERIMENTAL
Intervention: Brief Advice (BA)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement (ME)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 301
Study: 9221708

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enalapril (20 mg once daily)
Number of subjects: 100
Study: 8133796

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg every 3 weeks for 18 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 46
Study: 3628442

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg diazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.14 mg/kg diazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.21 mg/kg diazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31657840

Group type: EXPERIMENTAL
Intervention: Workplace SSB sales ban
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (no brief intervention)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Changes in SSB intake
Number of subjects: 214
Study: 29553444

Group type: EXPERIMENTAL
Intervention: Aggregate safety culture
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Hospital management support
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Non-punitive response to errors
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Communication and feedback on errors
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Teamwork
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Organisational learning
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Supervisor actions promoting patient safety
Number of subjects: 640
Study: 26244263

Group type: EXPERIMENTAL
Intervention: Customized tray during bleaching procedure
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bleaching techniques (with and without tray)
Number of subjects: 46
Study: 24950773

Group type: EXPERIMENTAL
Intervention: Local anaesthetic through MOTAP catheters
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline through MOTAP catheters (placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 120
Study: 22421420

Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide (S/N) anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-remifentanil (P/R) anesthesia
Number of subjects: 40
Study: 21153933

Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg 5% levobupivacaine + 0.1 mg morphine (Group M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal 10 mg 5% levobupivacaine + 20 mcg fentanyl (Group F)
Number of subjects: 60
Study: 18487730

Group type: EXPERIMENTAL
Intervention: CARDSS guideline-based decision support system
Number of subjects: 63
Study: 16002536

Group type: EXPERIMENTAL
Intervention: Oral ethinyl oestradiol (EE) with cyproterone acetate (CA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐oestradiol (E2) with cyproterone acetate (CA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cyproterone acetate (CA) only
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone esters
Number of subjects: 34
Study: 12540402

Group type: EXPERIMENTAL
Intervention: [(13)C]genistein
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: [(13)C]daidzein
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both [(13)C]daidzein and [(13)C]genistein
Number of subjects: 16
Study: 10928760

Group type: EXPERIMENTAL
Intervention: Mitomycin C treated group (0.2 mg/mL for five minutes)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (surgical excision alone)
Number of subjects: 35
Study: 8822681

Group type: EXPERIMENTAL
Intervention: Injection of 60mL saline and dextrose into the knee joint followed by submaximal exercise for 3 to 4 minutes
Number of subjects: 27

Group type: COMPARATOR
Intervention: No injection of fluid, followed by submaximal exercise for 3 to 4 minutes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Three maximum effort tests without any intervention
Number of subjects: 27
Study: 1424419

Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole administered once daily for 10 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered once daily for 10 days
Number of subjects: 12
Study: 3457234

Group type: EXPERIMENTAL
Intervention: Diet-Exercise (DE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sedentary Control (C)
Number of subjects: 96
Study: 29485326

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (FAS)
Number of subjects: 20
Study: 26150222

Group type: EXPERIMENTAL
Intervention: T2 ablation
Number of subjects: 22

Group type: COMPARATOR
Intervention: T2-T3 ablation
Number of subjects: 22
Study: 23300301

Group type: EXPERIMENTAL
Intervention: 0.2% whole yeast cell product (CitriStim) supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole yeast cell product (CitriStim) supplementation
Number of subjects: 0
Study: 21426372

Group type: COMPARATOR
Intervention: SB-656933 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: SB-656933 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: SB-656933 150 mg
Number of subjects: 0
Study: 19628647

Group type: EXPERIMENTAL
Intervention: Prednisone plus ramipril (combination therapy group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ramipril alone (monotherapy group)
Number of subjects: 97
Study: 16765398

Group type: EXPERIMENTAL
Intervention: Combination of sulfadoxine/pyrimethamine (single dose) and artesunate (3 daily doses of 4 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Amodiaquine and artesunate (3 daily doses)
Number of subjects: 27
Study: 15633617

Group type: EXPERIMENTAL
Intervention: Lithuanian mariners with hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: General population of Lithuania
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors associated with hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertension with other risk factors
Number of subjects: 0
Study: 11396558

Group type: EXPERIMENTAL
Intervention: Night vision goggles (NVG) at 3 or 10 footlamberts (fL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decrease in luminance levels below 0.03 fL
Number of subjects: 0
Study: 9754844

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (160 mg average daily dosage, highest permitted dose of 300 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7820711

Group type: EXPERIMENTAL
Intervention: Surfactant treatment (Curosurf), dosage and duration not specified
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Immediate response to surfactant treatment
Number of subjects: 253
Study: 3128137

Group type: EXPERIMENTAL
Intervention: 40% Ventimask with 10 litres/minute oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nasal cannula with 6 litres/minute oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nasal cannula with 9 litres/minute oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hudson mask with 3 litres/minute oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hudson mask with 6 litres/minute oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hudson mask with 9 litres/minute oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nasal cannula with 6 litres/minute humidified oxygen flow
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 40% Ventimask
Number of subjects: 71

Group type: COMPARATOR
Intervention: Unconscious state
Number of subjects: 71

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 71
Study: 31250126

Group type: EXPERIMENTAL
Intervention: Educational program based on the BASNEF model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 120
Study: 29192004

Group type: EXPERIMENTAL
Intervention: Comprehensive case management service (CCMS)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Usual care directed by their PCP
Number of subjects: 331
Study: 25438965

Group type: EXPERIMENTAL
Intervention: Reminder letter intervention
Number of subjects: 12205

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 12205
Study: 23164308

Group type: EXPERIMENTAL
Intervention: Immediate CPAP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Delayed CPAP (1 hour after presentation)
Number of subjects: 70
Study: 21594708

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) intravesical instillation within 24 hours of transurethral bladder resection (TURB)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) intravesical instillation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) treatment
Number of subjects: 211
Study: 18455085

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21900715

Group type: EXPERIMENTAL
Intervention: Induction arm (IA): pegylated interferon-α2a 270 μg/week plus ribavirin 1,600 mg daily for 4 weeks, followed by pegylated interferon-α2a at standard dosages plus weight-based ribavirin for 8 weeks.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard therapy arm (SA): pegylated interferon-α2a plus weight-based ribavirin for 12 weeks.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Induction arm (IA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard therapy arm (SA)
Number of subjects: 67
Study: 16273807

Group type: EXPERIMENTAL
Intervention: Various treatments from Swedish RA registry and biologics registries (ARTIS, SSATG, STURE)
Number of subjects: 0
Study: 11840671

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sevoflurane/N2O (50 vol%)
Number of subjects: 37
Study: 9814461

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment during pregnancy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 44
Study: 7897333

Group type: EXPERIMENTAL
Intervention: Initial ECG findings in women
Number of subjects: 373
Study: 2653552

Group type: EXPERIMENTAL
Intervention: Short overall treatment times (less than or equal to 4 weeks)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Long overall treatment times (greater than 4 weeks)
Number of subjects: 611
Study: 355965

Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29117309

Group type: EXPERIMENTAL
Intervention: Probiotic group (daily capsule with 109 total colony-forming units of Bifidobacterium lactis CECT 8145, B longum CECT 7347, Lactobacillus casei CECT 9104)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group (maltodextrin-only capsules)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 26826677

Group type: EXPERIMENTAL
Intervention: Intervention to improve clinician communication skills
Number of subjects: 383

Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 383

Group type: COMPARATOR
Intervention: Follow-up characteristics
Number of subjects: 383
Study: 24746581

Group type: EXPERIMENTAL
Intervention: Radiotherapy for painful bone metastases
Number of subjects: 1157
Study: 22511299

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 293

Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 293
Study: 20737519

Group type: EXPERIMENTAL
Intervention: 200 mg Panax ginseng (G115)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg Panax ginseng (G115)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18788838

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg three times daily
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg twice daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 244
Study: 15882219

Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial dose doxycycline (SDD) 20 mg twice daily with scaling and root planing (SRP)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 392
Study: 12851185

Group type: EXPERIMENTAL
Intervention: Weekly group exercise programme with ancillary home exercises
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 163
Study: 11026650

Group type: EXPERIMENTAL
Intervention: TNF‐α infusion without pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF‐α infusion after acetylsalicylic acid pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF‐α infusion after N(G)‐monomethyl‐L‐arginine pretreatment
Number of subjects: 0
Study: 8690112

Group type: EXPERIMENTAL
Intervention: Cytoplasmic aspiration before ICSI
Number of subjects: 58

Group type: COMPARATOR
Intervention: No cytoplasmic aspiration before ICSI
Number of subjects: 58
Study: 1880092

Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg tds)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Amoxycillin/Clavulanic acid (Augmentin; 750 mg tds)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin (1.2 g 8 hourly for 3 days, followed by oral doses as above for 7 days)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Amoxycillin/Clavulanic acid (Augmentin)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin
Number of subjects: 76
Study: 7146263

Group type: EXPERIMENTAL
Intervention: Bromazepam, 18 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80